Antihypertensive Response to Ketanserin: Influence of Race and Weight
The antihypertensive effects of the 5‐HT2 receptor antagonist ketanserin were evaluated in 16 patients with uncomplicated essential hypertension. Following a three week single‐blind placebo treatment period, patients were randomized to receive in a double‐blind manner oral ketanserin 20 mg or 40 mg...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacology 1988-11, Vol.28 (11), p.1017-1022 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1022 |
|---|---|
| container_issue | 11 |
| container_start_page | 1017 |
| container_title | Journal of clinical pharmacology |
| container_volume | 28 |
| creator | Kosoglou, Teddy Cressman, Michael D. Vlasses, Peter H. Rocci Jr, Mario L. Gabos, Christine Ferguson, Roger K. |
| description | The antihypertensive effects of the 5‐HT2 receptor antagonist ketanserin were evaluated in 16 patients with uncomplicated essential hypertension. Following a three week single‐blind placebo treatment period, patients were randomized to receive in a double‐blind manner oral ketanserin 20 mg or 40 mg twice a day for 10 weeks. In the racially mixed patient population, mean (±SD) seated blood pressure 12 hours after the last dose of placebo was 161 ± 11/99 ± 9 mm Hg and 155 ± 19/98 ± 10 mm Hg after ketanserin (P > .05). Ketanserin 20 mg twice a day did not lower blood pressure significantly. In contrast, 40 mg twice a day significantly decreased systolic blood pressure (P < .02), and lowered diastolic blood pressure (P = .06). White patients (N = 7) showed a significant decrease in blood pressure (BP) with ketanserin treatment (158 ± 5/98 ± 8 vs. 147 ± 13/92 ± 6 mm Hg, P < .05) while black patients (N = 9) did not (165 ± 13/100 ± 9 vs. 161 ± 21/102 ± 10 mm Hg, P > .05). For black patients only, significant correlations were observed between body weight and the change in diastolic BP (r = −.86, P < .005). The racial difference in response to ketanserin could not be attributed to differences between the two groups in age, sex, body weight, pretreatment blood pressure or ketanserin dose. The nature of the racial difference in the chronic antihypertensive response to ketanserin warrants further evaluation. |
| doi_str_mv | 10.1002/j.1552-4604.1988.tb03123.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78740583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78740583</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4383-1cadd3bbd774cd08a80825b88028113874ca64c82301673f9318b47023f045a03</originalsourceid><addsrcrecordid>eNqVkNFv0zAQxi0EGmXwJyBFCPGWcPY5sbsntmqsYxOgCdjeLMdxmEvqFDuF9r_HUaO-83Sn-7777vQj5A2FggKw96uCliXLeQW8oHMpi6EGpAyL3RMyO0pPyQxgTnMmAJ6TFzGuAGjFS3pCThAEQy5m5PLcD-5xv7FhsD66Pza7s3HT-2izoc9u7KBTG5w_y659222tNzbr2-xOp6p9k91b9_NxeEmetbqL9tVUT8n3j5ffFsv89svV9eL8NjccJebU6KbBum6E4KYBqSVIVtZSApOUokxTXXEjGaZHBbZzpLLmAhi2wEsNeEreHXI3of-9tXFQaxeN7Trtbb-NSqQIKCUm49nBaEIfY7Ct2gS31mGvKKiRoVqpEZQaQamRoZoYql1afj1d2dZr2xxXJ2hJfzvpOhrdtUF74-LRJrDiVVUl24eD7a_r7P4_HlCfFl-XY5si8kOEi4PdHSN0-KUSH1Gq-89X6gEvYP7wY6lu8B9fHpuy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78740583</pqid></control><display><type>article</type><title>Antihypertensive Response to Ketanserin: Influence of Race and Weight</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kosoglou, Teddy ; Cressman, Michael D. ; Vlasses, Peter H. ; Rocci Jr, Mario L. ; Gabos, Christine ; Ferguson, Roger K.</creator><creatorcontrib>Kosoglou, Teddy ; Cressman, Michael D. ; Vlasses, Peter H. ; Rocci Jr, Mario L. ; Gabos, Christine ; Ferguson, Roger K.</creatorcontrib><description>The antihypertensive effects of the 5‐HT2 receptor antagonist ketanserin were evaluated in 16 patients with uncomplicated essential hypertension. Following a three week single‐blind placebo treatment period, patients were randomized to receive in a double‐blind manner oral ketanserin 20 mg or 40 mg twice a day for 10 weeks. In the racially mixed patient population, mean (±SD) seated blood pressure 12 hours after the last dose of placebo was 161 ± 11/99 ± 9 mm Hg and 155 ± 19/98 ± 10 mm Hg after ketanserin (P > .05). Ketanserin 20 mg twice a day did not lower blood pressure significantly. In contrast, 40 mg twice a day significantly decreased systolic blood pressure (P < .02), and lowered diastolic blood pressure (P = .06). White patients (N = 7) showed a significant decrease in blood pressure (BP) with ketanserin treatment (158 ± 5/98 ± 8 vs. 147 ± 13/92 ± 6 mm Hg, P < .05) while black patients (N = 9) did not (165 ± 13/100 ± 9 vs. 161 ± 21/102 ± 10 mm Hg, P > .05). For black patients only, significant correlations were observed between body weight and the change in diastolic BP (r = −.86, P < .005). The racial difference in response to ketanserin could not be attributed to differences between the two groups in age, sex, body weight, pretreatment blood pressure or ketanserin dose. The nature of the racial difference in the chronic antihypertensive response to ketanserin warrants further evaluation.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1002/j.1552-4604.1988.tb03123.x</identifier><identifier>PMID: 3072347</identifier><identifier>CODEN: JCPCBR</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; African Continental Ancestry Group ; Aged ; Aldosterone - blood ; Aldosterone - urine ; Antihypertensive agents ; Biological and medical sciences ; Blood Pressure - drug effects ; Body Weight ; Cardiovascular system ; European Continental Ancestry Group ; Female ; Heart Rate - drug effects ; Humans ; Hypertension - drug therapy ; Hypertension - physiopathology ; Ketanserin - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Renin - blood</subject><ispartof>Journal of clinical pharmacology, 1988-11, Vol.28 (11), p.1017-1022</ispartof><rights>1988 American College of Clinical Pharmacology</rights><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4383-1cadd3bbd774cd08a80825b88028113874ca64c82301673f9318b47023f045a03</citedby><cites>FETCH-LOGICAL-c4383-1cadd3bbd774cd08a80825b88028113874ca64c82301673f9318b47023f045a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fj.1552-4604.1988.tb03123.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fj.1552-4604.1988.tb03123.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7364666$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3072347$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kosoglou, Teddy</creatorcontrib><creatorcontrib>Cressman, Michael D.</creatorcontrib><creatorcontrib>Vlasses, Peter H.</creatorcontrib><creatorcontrib>Rocci Jr, Mario L.</creatorcontrib><creatorcontrib>Gabos, Christine</creatorcontrib><creatorcontrib>Ferguson, Roger K.</creatorcontrib><title>Antihypertensive Response to Ketanserin: Influence of Race and Weight</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>The antihypertensive effects of the 5‐HT2 receptor antagonist ketanserin were evaluated in 16 patients with uncomplicated essential hypertension. Following a three week single‐blind placebo treatment period, patients were randomized to receive in a double‐blind manner oral ketanserin 20 mg or 40 mg twice a day for 10 weeks. In the racially mixed patient population, mean (±SD) seated blood pressure 12 hours after the last dose of placebo was 161 ± 11/99 ± 9 mm Hg and 155 ± 19/98 ± 10 mm Hg after ketanserin (P > .05). Ketanserin 20 mg twice a day did not lower blood pressure significantly. In contrast, 40 mg twice a day significantly decreased systolic blood pressure (P < .02), and lowered diastolic blood pressure (P = .06). White patients (N = 7) showed a significant decrease in blood pressure (BP) with ketanserin treatment (158 ± 5/98 ± 8 vs. 147 ± 13/92 ± 6 mm Hg, P < .05) while black patients (N = 9) did not (165 ± 13/100 ± 9 vs. 161 ± 21/102 ± 10 mm Hg, P > .05). For black patients only, significant correlations were observed between body weight and the change in diastolic BP (r = −.86, P < .005). The racial difference in response to ketanserin could not be attributed to differences between the two groups in age, sex, body weight, pretreatment blood pressure or ketanserin dose. The nature of the racial difference in the chronic antihypertensive response to ketanserin warrants further evaluation.</description><subject>Adult</subject><subject>African Continental Ancestry Group</subject><subject>Aged</subject><subject>Aldosterone - blood</subject><subject>Aldosterone - urine</subject><subject>Antihypertensive agents</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Body Weight</subject><subject>Cardiovascular system</subject><subject>European Continental Ancestry Group</subject><subject>Female</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>Ketanserin - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Renin - blood</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkNFv0zAQxi0EGmXwJyBFCPGWcPY5sbsntmqsYxOgCdjeLMdxmEvqFDuF9r_HUaO-83Sn-7777vQj5A2FggKw96uCliXLeQW8oHMpi6EGpAyL3RMyO0pPyQxgTnMmAJ6TFzGuAGjFS3pCThAEQy5m5PLcD-5xv7FhsD66Pza7s3HT-2izoc9u7KBTG5w_y659222tNzbr2-xOp6p9k91b9_NxeEmetbqL9tVUT8n3j5ffFsv89svV9eL8NjccJebU6KbBum6E4KYBqSVIVtZSApOUokxTXXEjGaZHBbZzpLLmAhi2wEsNeEreHXI3of-9tXFQaxeN7Trtbb-NSqQIKCUm49nBaEIfY7Ct2gS31mGvKKiRoVqpEZQaQamRoZoYql1afj1d2dZr2xxXJ2hJfzvpOhrdtUF74-LRJrDiVVUl24eD7a_r7P4_HlCfFl-XY5si8kOEi4PdHSN0-KUSH1Gq-89X6gEvYP7wY6lu8B9fHpuy</recordid><startdate>198811</startdate><enddate>198811</enddate><creator>Kosoglou, Teddy</creator><creator>Cressman, Michael D.</creator><creator>Vlasses, Peter H.</creator><creator>Rocci Jr, Mario L.</creator><creator>Gabos, Christine</creator><creator>Ferguson, Roger K.</creator><general>Blackwell Publishing Ltd</general><general>Sage Science</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198811</creationdate><title>Antihypertensive Response to Ketanserin: Influence of Race and Weight</title><author>Kosoglou, Teddy ; Cressman, Michael D. ; Vlasses, Peter H. ; Rocci Jr, Mario L. ; Gabos, Christine ; Ferguson, Roger K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4383-1cadd3bbd774cd08a80825b88028113874ca64c82301673f9318b47023f045a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Adult</topic><topic>African Continental Ancestry Group</topic><topic>Aged</topic><topic>Aldosterone - blood</topic><topic>Aldosterone - urine</topic><topic>Antihypertensive agents</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Body Weight</topic><topic>Cardiovascular system</topic><topic>European Continental Ancestry Group</topic><topic>Female</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>Ketanserin - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Renin - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kosoglou, Teddy</creatorcontrib><creatorcontrib>Cressman, Michael D.</creatorcontrib><creatorcontrib>Vlasses, Peter H.</creatorcontrib><creatorcontrib>Rocci Jr, Mario L.</creatorcontrib><creatorcontrib>Gabos, Christine</creatorcontrib><creatorcontrib>Ferguson, Roger K.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kosoglou, Teddy</au><au>Cressman, Michael D.</au><au>Vlasses, Peter H.</au><au>Rocci Jr, Mario L.</au><au>Gabos, Christine</au><au>Ferguson, Roger K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antihypertensive Response to Ketanserin: Influence of Race and Weight</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>1988-11</date><risdate>1988</risdate><volume>28</volume><issue>11</issue><spage>1017</spage><epage>1022</epage><pages>1017-1022</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><coden>JCPCBR</coden><abstract>The antihypertensive effects of the 5‐HT2 receptor antagonist ketanserin were evaluated in 16 patients with uncomplicated essential hypertension. Following a three week single‐blind placebo treatment period, patients were randomized to receive in a double‐blind manner oral ketanserin 20 mg or 40 mg twice a day for 10 weeks. In the racially mixed patient population, mean (±SD) seated blood pressure 12 hours after the last dose of placebo was 161 ± 11/99 ± 9 mm Hg and 155 ± 19/98 ± 10 mm Hg after ketanserin (P > .05). Ketanserin 20 mg twice a day did not lower blood pressure significantly. In contrast, 40 mg twice a day significantly decreased systolic blood pressure (P < .02), and lowered diastolic blood pressure (P = .06). White patients (N = 7) showed a significant decrease in blood pressure (BP) with ketanserin treatment (158 ± 5/98 ± 8 vs. 147 ± 13/92 ± 6 mm Hg, P < .05) while black patients (N = 9) did not (165 ± 13/100 ± 9 vs. 161 ± 21/102 ± 10 mm Hg, P > .05). For black patients only, significant correlations were observed between body weight and the change in diastolic BP (r = −.86, P < .005). The racial difference in response to ketanserin could not be attributed to differences between the two groups in age, sex, body weight, pretreatment blood pressure or ketanserin dose. The nature of the racial difference in the chronic antihypertensive response to ketanserin warrants further evaluation.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>3072347</pmid><doi>10.1002/j.1552-4604.1988.tb03123.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-2700 |
| ispartof | Journal of clinical pharmacology, 1988-11, Vol.28 (11), p.1017-1022 |
| issn | 0091-2700 1552-4604 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78740583 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult African Continental Ancestry Group Aged Aldosterone - blood Aldosterone - urine Antihypertensive agents Biological and medical sciences Blood Pressure - drug effects Body Weight Cardiovascular system European Continental Ancestry Group Female Heart Rate - drug effects Humans Hypertension - drug therapy Hypertension - physiopathology Ketanserin - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments Renin - blood |
| title | Antihypertensive Response to Ketanserin: Influence of Race and Weight |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T16%3A49%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antihypertensive%20Response%20to%20Ketanserin:%20Influence%20of%20Race%20and%20Weight&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Kosoglou,%20Teddy&rft.date=1988-11&rft.volume=28&rft.issue=11&rft.spage=1017&rft.epage=1022&rft.pages=1017-1022&rft.issn=0091-2700&rft.eissn=1552-4604&rft.coden=JCPCBR&rft_id=info:doi/10.1002/j.1552-4604.1988.tb03123.x&rft_dat=%3Cproquest_cross%3E78740583%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78740583&rft_id=info:pmid/3072347&rfr_iscdi=true |